Inquis Medical raised $75 million in a Series C announced January 12, 2026. The company named no investor, describing the backer only as a strategic. Marshall Wace led the $40 million Series B in August 2024, and total funding now exceeds $115 million. Founded in 2020 in Menlo Park, California, Inquis is run by co-founders and co-CEOs Vahid Saadat and Mojgan Saadat.
Aventus is a directional aspiration thrombectomy system for venous thromboembolism that reinfuses the patient's own blood. Tissue sensing tells clot from blood and vessel wall. FDA first cleared it under K232730 in November 2023 and added the pulmonary embolism indication under K251189 on June 13, 2025, a 57-day review. A study in 130 intermediate-risk PE patients, published in JSCAI, reported no device-related adverse events.
Proceeds fund a nationwide sales and physician-training build-out and next-generation products. Three days after the announcement, FDA cleared a further Aventus 510(k), K253925, which had been received December 8. An unnamed strategic writing the whole $75 million is usually a large company keeping an acquisition option open.